Study Stopped
Drug not available
Role of Oxytocin in Telling and Detecting Lies
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
The investigators are interested in the impact of intranasal oxytocin in unethical behavior.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jan 2016
Shorter than P25 for early_phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 5, 2015
CompletedFirst Posted
Study publicly available on registry
February 11, 2015
CompletedStudy Start
First participant enrolled
January 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedJune 13, 2016
June 1, 2016
3 months
February 5, 2015
June 9, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Unethical behavior
To measure unethical behavior, we will calculate whether participants took more money than they actually earned on a problem-solving task.
130 minutes
Study Arms (2)
oxytocin
EXPERIMENTALIntranasal 24 IU oxytocin self-administration.
placebo
PLACEBO COMPARATORIntranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
Interventions
Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
Eligibility Criteria
You may qualify if:
- Male
You may not qualify if:
- \_\_\_\_\_ \_\_\_\_\_BP \> 130/85, HRT \> 95 (can be included at discretion of study physician/designee)
- \_\_\_\_\_History of seizures
- \_\_\_\_\_Neurological Disorder
- \_\_\_\_\_Current psychiatric disorder
- \_\_\_\_\_Previous psychiatric disorder (can be included at discretion of PI)
- Date last episode (if \> 1 year, include; if \<1 year, at discretion of PI)
- \_\_\_\_\_Current use of psychoactive drugs
- \_\_\_\_\_Previous use of psychoactive drugs (can be included at discretion of PI) \_\_\_\_\_Date last medicated\_\_\_\_\_ \_\_\_\_\_Type of medication\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
- \_\_\_\_\_Current use of anticoagulants
- \_\_\_\_\_Current use of corticosteroids
- \_\_\_\_\_Previous head trauma (can be included at discretion of PI)
- \_\_\_\_\_Alcoholism or substance abuse
- \_\_\_\_\_Carcinoma of the breast or prostate
- \_\_\_\_\_Renal or Hepatic diseases
- \_\_\_\_\_Chronic lung diseases
- +13 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Texas at Austinlead
- Harvard Universitycollaborator
Related Publications (1)
Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005 Jun 2;435(7042):673-6. doi: 10.1038/nature03701.
PMID: 15931222RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Robert A Josephs, PhD
utaustin
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 5, 2015
First Posted
February 11, 2015
Study Start
January 1, 2016
Primary Completion
April 1, 2016
Study Completion
April 1, 2016
Last Updated
June 13, 2016
Record last verified: 2016-06